drugset / Trial / NCT00880464

Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer

NCT00880464 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer. The vaccine is made by genetically modifying a patient's own tumor cells to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate the immune response

Timeline

Start
2006-01-01
Primary completion
2011-10
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous, Lethally Irradiated Breast Cancer Cells Vaccine 100000 cells Subcutaneous
Subject Autologous, Lethally Irradiated Breast Cancer Cells Vaccine 1e+06 cells Subcutaneous
Subject Autologous, Lethally Irradiated Breast Cancer Cells Vaccine 4e+06 cells Subcutaneous
Subject Autologous, Lethally Irradiated Breast Cancer Cells Vaccine 1e+07 cells Subcutaneous

Indications